Cytokinetics (CYTK) Tops Q3 EPS by 7c

Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 39c
• Cytokinetics (CYTK) PT Raised to $112 at Truist Securities